Tirzepatide linked to lower stroke risk than other GLP-1 drugs in atrial fibrillation

A new analysis published in Nature Communications on August 22, 2026, found that tirzepatide, sold as Mounjaro and Zepbound, was linked to lower rates of stroke and death compared with older GLP-1 receptor agonist drugs in people who have both atrial fibrillation and type 2 diabetes ^[1]. The study is observational, meaning it looked at existing patient records rather than randomly assigning people to different drugs.

Researchers used a large international database of de-identified electronic health records called the TriNetX Global Collaborative Network ^[1]. They matched 14,118 pairs of adults who started tirzepatide against adults who started another GLP-1 receptor agonist, pairing people with similar health backgrounds so the two groups would be as alike as possible ^[1]. Everyone in the study had both atrial fibrillation, an irregular heartbeat condition that raises stroke risk, and type 2 diabetes ^[1].

The people who took tirzepatide had lower risks of any stroke, ischemic stroke, hemorrhagic stroke, and death from any cause than those who took the other drugs ^[1]. At one year, the absolute difference in stroke risk was 2.1 percentage points, and the absolute difference in death from any cause was 6.2 percentage points, favoring tirzepatide ^[1]. An absolute difference of this kind means the actual gap in how many people in each group had the outcome, not just a relative comparison.

The study's authors, led by researchers affiliated with several hospitals and universities in Taiwan, wrote that these findings support further study of tirzepatide as a possible option for people who have both atrial fibrillation and type 2 diabetes ^[1]. But they were direct about the limits of their work: because this was a retrospective look at health records rather than a randomized trial, randomized trials are required before any treatment recommendations can change ^[1].

Why it matters for patients

Many people who read about GLP-1 drugs want to know if one option is safer than another for a specific health condition, and atrial fibrillation combined with diabetes is a common and serious combination that already carries a higher baseline stroke risk even with standard treatment such as blood thinners and glucose control ^[1]. This study adds new data suggesting tirzepatide may be linked to fewer strokes and lower death rates than other GLP-1 drugs in this specific patient group, but it does not prove that tirzepatide causes fewer strokes ^[1].

Observational studies like this one can be affected by factors the researchers could not fully account for, even after matching patients on health characteristics. People who get prescribed a newer, and often more expensive, drug like tirzepatide may differ from those prescribed older options in ways not captured in health records, such as income, other care they receive, or how closely they are monitored. The study's own authors flagged this limitation by calling for randomized trials, which assign patients to treatments by chance and are considered stronger evidence for guiding care decisions ^[1].

For now, the findings are a signal for further research rather than a basis for changing what drug someone with atrial fibrillation and diabetes is prescribed. No medical body has updated treatment guidance based on this single study, and the paper does not describe any regulatory or clinical practice changes tied to its publication ^[1].

What happens next

The study was published August 22, 2026, in Nature Communications, alongside supplementary data and a peer review file ^[1]. The authors state that randomized controlled trials are still needed before these findings could inform treatment recommendations, though the source material does not name a specific trial, sponsor, or timeline for such a study ^[1].